Zura Bio (NASDAQ:ZURA) Announces Earnings Results, Beats Expectations By $0.09 EPS

Zura Bio (NASDAQ:ZURA) issued its quarterly earnings data on Tuesday. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.09, Zacks reports. The business had revenue of $0.00 million during the quarter.

Zura Bio Stock Performance

NASDAQ ZURA traded up $0.04 on Thursday, hitting $1.38. 41,895 shares of the company’s stock traded hands, compared to its average volume of 351,005. Zura Bio has a 1-year low of $1.07 and a 1-year high of $6.35. The firm’s 50-day moving average price is $1.48 and its two-hundred day moving average price is $2.76.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE raised its stake in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 41,222 shares of the company’s stock after buying an additional 9,966 shares during the period. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 at the end of the most recent quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ZURA. Oppenheimer reissued an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research note on Wednesday. Guggenheim restated a “buy” rating and set a $15.00 price target on shares of Zura Bio in a report on Wednesday. HC Wainwright reiterated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Chardan Capital lowered their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $15.00.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.